GCG and type 2 diabetes mellitus: Originally developed for the management of obesity and type 2 diabetes, GLP-1 agonists have recently been tested in populations with both obesity and OSA, showing encouraging results in reducing OSA severity through weight loss and possibly other mechanisms.